Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Globe Newswire•14/10/2026•08:00 ET
0
Key Highlights
- ➤ReWalk used median 33 months, with no reported falls or exoskeleton-related fractures
- ➤Six of seven participants recorded more than 3,000 monthly steps
- ➤User satisfaction reached median QUEST score 4.2 out of 5
- ➤Participants reported median 3-point bowel and bladder improvements and 4-point pain reduction
- ➤Median six-minute walk reached 129 meters without stopping after prolonged home use
Expert Statements
Keith Rose, Chief Medical Officer of Lifeward
“This study represents an important advance in the evidence supporting personal exoskeleton use because it demonstrates what can be achieved beyond the initial rehabilitation and training period.”
Keith Rose, Chief Medical Officer of Lifeward
“After years of access to ReWalk in their homes, individuals with chronic paraplegia demonstrated measurable walking performance, including a median distance of 129 meters in the six-minute walk test without stopping to rest.”
Keith Rose, Chief Medical Officer of Lifeward
“These findings show the potential for long-term ReWalk use to enable appropriately selected individuals with paraplegia to continue standing and walking years after receiving their systems.”
Josh Hexter, Interim Chief Executive Officer of Lifeward
“Evidence that people are continuing to use ReWalk years after receiving their systems is particularly meaningful as we work to expand access to the technology.”
Josh Hexter, Interim Chief Executive Officer of Lifeward
“The growing body of peer-reviewed evidence supporting ReWalk, which now includes these long-term real-world findings, can help patients, clinicians and payers better understand the role personal exoskeleton technology can play in the lives of appropriately selected individuals with spinal cord injury.”
Josh Hexter, Interim Chief Executive Officer of Lifeward
“We believe this supports our patient-centered and commercial efforts to provide ReWalk to all patients that can benefit from our market-leading exoskeleton technology.”
Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia
ReWalk was used for a median of 33 months, with no reported falls or exoskeleton-related fractures during the observation period; participants maintained 3,000+ steps per month, demonstrating sustained real-world utilization
Get started
Create a free account to read the full story.